Carbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2011 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS)

Table 1 Carbapenem non-susceptibility of K. pneumoniae isolates in Germany 2011–2016 (n = 154,734)

Tested carbapenem	Number of isolates tested (% of all isolates)	Isolates tested “susceptible” (% with 95% CI)^a	Isolates tested “intermediate” (% with 95% CI)^a	Isolates tested “resistant” (% with 95% CI)^a	Isolates tested “non-susceptible” (% with 95% CI)^a
Meropenem	150,746 (97.4%)	99.58% (99.49, 99.65%)	0.09% (0.07, 0.12%)	0.33% (0.27, 0.40%)	0.42% (0.35, 0.51%)
Imipenem	150,114 (97.0%)	99.62% (99.54, 99.69%)	0.11% (0.09, 0.14%)	0.27% (0.22, 0.34%)	0.38% (0.31, 0.46%)
Ertapenem	56,560 (36.6%)	98.95% (98.68, 99.16%)	0.11% (0.08, 0.16%)	0.94% (0.74, 1.2%)	1.05% (0.84, 1.32%)
At least one carbapenem^b	154,524 (99.9%)	99.37% (99.24, 99.49%)	0.11% (0.08, 0.13%)	0.52% (0.42, 0.64%)	0.63% (0.51, 0.76%)

ISSN: 2047-2994